R&D On incentivisation and investment in rare disease R&D To mark Rare Disease Day, pharmaphorum spoke with Paola Pozzi, partner of telethon strategy at Sofinnova Partners, about the outlook for investment in this field of research.
R&D Will 2025 be the year the pharmaceutical industry finds its ... After spending 2024 in recovery mode, the biopharma industry is finally showing signs of growth, climbing back toward its pre-pandemic heights.
Market Access The outlook for healthtech and life sciences in 2025 2024 was pivotal for UK Life Sciences’ venture funding landscape.
News Report says AZ's UK plant decision is not just about funding It's been reported that the UK government made an offer of £78 million in funding for AstraZeneca's abandoned £450 million vaccine facility in Speke.
News AstraZeneca abandons plan for £450m vaccine plant in UK In a shock move, AstraZeneca has ditched its plan to invest £450m in a new vaccine manufacturing plant in the UK.
News AstraZeneca reveals $570m investment in Canada AstraZeneca has announced another major investment in Canada, tapping into the country's emergence as a "global hub" for clinical trials.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.